- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03917732
Cognitive Therapy for Urinary Dysfunction in Parkinson´s Disease (PD-UD)
Randomized Controlled Study to Evaluate the Efficacy of a Cognitive Training Approach to Improve Urinary Dysfunction in Parkinson's Disease
Idiopathic Parkinson's syndrome (IPS) is one of the most common neurodegenerative diseases. The prevalence and significance of this disease is continuously increasing in the course of demographic change. For many decades, the focus of diagnostics and therapy was on the motor symptoms of IPS. Only in recent years, it has been recognized that Parkinson's patients also suffer from a variety of non-motor symptoms. These have a decisive influence on the patient's quality of life. As one of the most common non-motor symptoms, 55 to 80% of IPS patients suffer from urinary dysfunction. This is associated with a very high impairment of quality of life due to a high degree of stigmatization and impairment of social participation. In clinical everyday life, Parkinson's patients regularly report the occurrence of a strong imperative urge to urinate, which occurs suddenly and is usually triggered by a certain external stimuli. Specific cognitive processing and reflection of these external stimuli seems to help overcome the imperative urge to urinate. From this clinical observation, it can be assumed that the imperative urge to urinate is subject to a certain cognitive control in the sense of targeted inhibition.
The pharmacological therapy of urinary dysfunction in IPS patients is severely restricted and characterized by insufficient proof of efficacy as well as a high potential for side effects. In clinical practice, alpha-blockers and anticholinergics are frequently used, but the evidence base for IPS is inadequate. In addition, there is a highly relevant risk for Parkinson's patients of specific side effects such as orthostatic dysregulation or deterioration of cognition up to psychoses and hallucinations. This greatly limits their use especially in older IPS patients. While the use of dopaminergic medication is essential for the treatment of motor symptoms in Parkinson's patients, a large number of studies have not confirmed sufficient evidence for the efficacy of dopaminergic medication in urinary dysfunction. In addition, non-pharmacological therapy options, in particular pelvic floor training, are used to treat bladder dysfunction. Due to the lack of risk of side effects, pelvic floor training is currently recommended as a first-line therapy option for IPS patients. Initial studies have shown positive effects, but due to the lack of randomized controlled trials, a sufficient evidence base for this has not yet been established.
The aim of the study is to examine whether a purely cognitive therapy approach is suitable to improve subjective and objective symptoms of urinary dysfunction in IPS patients. This therapeutic approach will be compared with the gold standard of pelvic floor training in terms of efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Inken Rothkirch, Dr. phil.
- Phone Number: 0431 500 23985
- Email: i.rothkirch@neurologie.uni-kiel.de
Study Locations
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
- Recruiting
- Department of Neurology, University Hospital Schleswig-Holstein
-
Contact:
- Inken Rothkirch, Dr. phil.
- Phone Number: 0431 500 23985
- Email: i.rothkirch@neurologie.uni-kiel.de
-
Principal Investigator:
- Inken Rothkirch, Dr. phil.
-
Principal Investigator:
- Eva Schaeffer, Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- consenting capacity (MOCA >17) and written consent
- idiopathic parkinson syndrome according to UK Brain Bank criteria
- female gender
Exclusion Criteria:
- missing consenting capacity (MOCA <18)
- current depressive episode (BDI > 18)
- current intake of medication for the treatment of bladder dysfunction
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: cognitive training
The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques. The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes. |
The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques. The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes. |
ACTIVE_COMPARATOR: pelvic floor training
At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns. The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes. |
At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns. The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the International Consultation on Incontinence Questionnaire Overactive Bladder Module (ICIQ-OAB)
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The ICIQ-OAB is a questionnaire for evaluating overactive bladder and related impact on quality of life (QoL) and outcome of treatment in men and women in research and clinical practice across the world.
The ICIQ-OAB is derived from the fully validated ICSmale and BFLUTS questionnaires and provides a measure to assess the impact of urinary frequency, urgency, urge incontinence and nocturia symptoms.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the International Consultation on Incontinence Questionnaire Lower Urinary Tract Symptoms Quality of Life Module (ICIQ-LUTSqol)
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The ICIQ-LUTSqol is a psychometrically robust patient-completed questionnaire evaluating quality of life (QoL) in urinary incontinent patients for use in research and clinical practice across the world.
The ICIQ-LUTSqol is the King's Health Questionnaire (KHQ) adapted for use within the ICIQ structure and provides a measure to assess the impact of urinary incontinence on quality of life with particular reference to social effects.
It is an ideal research tool as it explores in detail the impact on patients' lives of urinary incontinence and can be used as an outcome measure to assess impact of different treatment modalities.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Patient Perception of Bladder Condition (PPBC)
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The PPBC is a single-item, global outcome measure for urinary incontinence.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the International Prostate Symptom Score (I-PSS)
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life.
Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom.
The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Uroflowmetric
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
Uroflowmetry measures the flow of urine.
It tracks how fast urine flows, how much flows out, and how long it takes.
It's a diagnostic test to assess how well the urinary tract functions.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Verbal memory function through the Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat.
Another list of 15 unrelated words are given and the client must again repeat the original list of 15 words and then again after 30 minutes.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Visuomotor abilities and nonverbal memory Rey-Osterrieth complex figure test (ROCF)
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The Rey-Osterrieth complex figure test (ROCF) is a neuropsychological assessment in which patients are asked to reproduce a complicated line drawing, first by copying it freehand (recognition; measures visuomotor abilities), and then drawing from memory (recall; measures nonverbal memory).
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Verbal short term memory functions through the Digit Span test
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
Verbal short term memory span measures the number of discrete units over which the patient can successively distribute his attention and still organize them into a working unit.
To generalize, it refers to the ability of the patient to reproduce immediately, after one presentation, a series of discrete stimuli in their original order.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Response inhibition through the Stroop test
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The Stroop test is a widely used measure of selective attention that requires interference resolution, response inhibition, and response selection.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Visual attention and task switching though the Trial Making Test
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The Trail Making Test is a neuropsychological test of visual attention and task switching.
It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Change in the Word fluency through the Regensburger Word Fluency Test
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
In the Regensburger Word Fluency Test patients have to produce as many words as possible from a given category or beginning with a specific letter within 2 minutes.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in functional magnet resonance imaging (fMRI) within a Go/NoGo paradigm
Time Frame: 4 weeks before beginning and 4 weeks after completion of the training
|
The investigators aim to answer the question whether there are different activity patterns in Parkinson's patients with bladder dysfunction compared to Parkinson's patients without bladder dysfunction in the areas involved in bladder function regulation while concerning a Go/NoGo paradigm.
|
4 weeks before beginning and 4 weeks after completion of the training
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Daniela Berg, Prof. Dr., Department of Neurology, University Hospital Schleswig- Holstein
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D418/19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on cognitive training
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
Hospital de Clinicas de Porto AlegreYale UniversityUnknownAttention-deficit/Hyperactivity Disorder.Brazil
-
Universidade Federal do Rio de JaneiroUnknown
-
Xuanwu Hospital, BeijingRecruitingMild Cognitive ImpairmentChina
-
Chang Gung Memorial HospitalRecruitingVirtual Reality | Community-dwelling ElderlyTaiwan
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Chiang Mai UniversityCompletedMild Cognitive ImpairmentThailand
-
Chang Gung Memorial HospitalRecruitingMCI | SCD | Virtual RealityTaiwan
-
University of California, San FranciscoCompletedSchizophrenia | PsychosisUnited States
-
VA Office of Research and DevelopmentCompleted